SUO 2018: Metastasectomy: Update on the Evidence
Phoenix, Arizona (UroToday.com) The optimal treatment for patients with oligometastatic renal cell carcinoma remains controversial. As part of the advanced kidney cancer section of the 2018 Society of Urologic Oncology Annual Meeting, Dr. Viraj Master from Emory University reviewed the literature regarding the efficacy of metastasectomy in patients with metastatic renal cell carcinoma (RCC). Dr. Master began the talk by acknowledging that there are no randomized trials in RCC that compare metastasectomy to systemic therapy, and therefore decisions to perform metastasectomy vary between institutions and physicians.
SUO 2018: Update on the SEMS Trial - Surgery in Early Metastatic Seminoma
Phoenix, Arizona (UroToday.com) Dr. Daneshmand wrapped up the testicular cancer session with an update on the SEMS trial. The current standard of care for node-positive seminoma patients is either radiation or chemotherapy. There has been no change in recommendation for decades. However, as seen by Dr. Travis’ work, these treatments are associated with long-term morbidity, such as 2nd malignancy, cardiovascular toxicity, metabolic syndrome, and pulmonary toxicity. Especially as the cure rates are so high, patients have a long time to develop these toxicities.
SUO 2018: POUT Trial - Adjuvant Therapy for Upper Tract Urothelial Carcinoma
Phoenix, Arizona (UroToday.com) Sandy Srinivas, MD summarized the results from the POUT trial in upper tract urothelial carcinoma (UTUC) patients. Treatment of patients with UTUC is still controversial due to the fact that this is a rare disease and that level 1 evidence is lacking. Radical nephroureterectomy surgery is considered the standard of care for patients with high-grade disease or for those with muscle-invasive disease. There is some evidence supporting the role of using platinum-based chemotherapy either in the form of neoadjuvant or adjuvant treatment.
SUO 2018: Upper Urinary Tract Transitional Cell Carcinoma: Neoadjuvant Chemotherapy Prior to Nephroureterectomy
Phoenix, Arizona (UroToday.com) Dr. Hoffman-Cencis presented the role of neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma. Neoadjuvant chemotherapy results in complete response of 38% of the patients with bladder tumors, compared to only 9-14% in upper tract disease. The reasons for this difference are not entirely clear.
SUO 2018: Targeting the Adaptive Molecular Landscape of Castration-Resistant Prostate Cancer
Phoenix, Arizona (UroToday.com) Following a glowing introduction by Dr. Christopher Evans and receipt of the Huggins Medal by Dr. Gleave, Dr. Gleave gave a talk on targeting the adaptive molecular landscape of castration-resistant prostate cancer (CRPC).
SUO 2018: Adding Topical Therapy to Endoscopic Treatment for Upper Tract Urothelial Carcinoma
Phoenix, Arizona (UroToday.com) Dr. Chamie gave a talk on the use of topical agents in upper tract urothelial carcinoma. According to the European Association of Urology (EAU) guidelines, low-risk disease can be treated with endoscopic strategies. Low-grade disease is characterized by unifocal disease, tumor size less than 2 cm, low-grade cytology, low-grade biopsy result, and no invasive aspect on CT scans. In the “real world” there is an increasing trend for endoscopic management in low-risk disease (from 6-11% in tumors of the renal pelvis and from 17% to 20% for tumors in the ureter).1
SUO 2018: Cancer as a Health Shock: Adverse Financial and Employment Outcomes
Phoenix, Arizona (UroToday.com) Health shock is defined by the world health organization as a large unanticipated adverse health event. In this session, Dr. Veenstra discussed her research and patient experiences with health shock in order to help attendees better advocate for their patients.